基于残余的多阶段深度学习框架,用于计算机辅助的阿尔茨海默氏病检测
Najmul Hassan1, Abu Saleh Musa Miah1, Jungpil Shin1
1School of Computer Science and Engineering, The University of Aizu, Aizuwakamatsu 965-8580, Japan.
Journal of imaging
|June 26, 2024
概括
一个新的多阶段深度神经网络准确地检测阿尔茨海默病 (AD). 这种先进的系统显示了高精度,为早期AD检测和医学成像分析提供了显著的改进.
科学领域:
- 神经学 神经学
- 医疗成像医学成像
- 人工智能的人工智能
背景情况:
- 阿尔茨海默病 (AD) 是全球痴呆的主要原因,影响超过50%的日本老年人.
- 目前的AD检测方法与深度学习模型的复杂性作斗争.
- 对于自动化和准确的AD检测系统有着至关重要的需求.
研究的目的:
- 引入一种新的多阶段深度神经网络,用于增强阿尔茨海默病的检测.
- 在AD分析中解决现有的等级卷积神经网络 (CNN) 的局限性.
- 提高自动化AD检测系统的准确性和效率.
主要方法:
- 一个五阶段的深度神经网络架构,利用剩余函数进行功能增强.
- 集成基于深度学习的功能选择模块与批量规范化,丢弃和完全连接的层进行集成,以防止过.
- 使用机器学习算法进行分类:支持矢量机器 (SVM),随机森林 (RF) 和SoftMax.
主要成果:
- 拟议的模型实现了高准确率:在ADNI1上达到99.47%,在MIRAID上达到99.10%,在OASIS Kaggle数据集上达到99.70%.
- 该系统在二进制分类任务中表现出比现有方法更高的性能.
- 多级架构有效地增强了特征提取和模型深度.
结论:
- 这种新型的多阶段深度神经网络在阿尔茨海默病分析方面取得了重大进展.
- 该模型的高精度表明它有可能用于可靠的自动AD检测.
- 这种方法为更有效的早期诊断和阿尔茨海默病的管理铺平了道路.
更多相关视频
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.2K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.5K
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
